A thymic polypeptide bioregulator that modulates immune function — widely used in Russian gerontology.
Thymalin is a polypeptide extract from bovine thymus glands, developed by Dr. Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It contains a mixture of low-molecular-weight thymic peptides and represents an early-generation thymic bioregulator — predating the more purified Thymosin Alpha-1.
Like Thymosin Alpha-1, thymalin promotes thymic function and T-cell immunity — particularly important in aging populations where the thymus has atrophied. It acts as a 'bioregulator' — a peptide that normalizes physiological function rather than producing supraphysiological effects.
Thymalin has been a cornerstone of Russian gerontological medicine for decades. It is registered in Russia and used in clinical practice for immune deficiency states, post-chemotherapy immune recovery, chronic infections, and aging-related immune decline. Long-term use studies (15+ years) have been published from Khavinson's group.
Khavinson's group published 15-year follow-up data showing that elderly patients who received periodic thymalin courses had significantly improved survival compared to controls. Immune parameters (T-lymphocyte counts, NK cell activity) showed sustained improvements.
Multiple peer-reviewed publications from Russian institutions document thymalin's immunomodulatory effects. Independent replication in Western clinical trials is limited, but the historical and longitudinal Russian data is more extensive than for most peptides in the longevity space.
📚 Key Reference: PMID: 16842800 (Thymalin 15-year study)
Long clinical track record in Russian medicine. Generally well-tolerated. IM injection site reactions. As a bovine thymus extract (protein mixture), allergic reactions are theoretically possible. The manufacturing and purity standards of US compounded versions may differ from Russian pharmaceutical-grade preparations. Consult your provider.
Approved in Russia as a pharmaceutical. NOT FDA-approved in the US. Available through specialized compounding pharmacies. Regulatory framework in the US is under the 503A/503B compounding pharmacy rules.